Evaluation of Low Erythropoietin in Patients with Normal Hemoglobin

Normal Reference Values for Erythropoietin

• The expected serum erythropoietin concentration in healthy adults is 10–30 mU/mL. 1

Diagnostic Significance of Suppressed Erythropoietin

• A low serum erythropoietin level is highly specific (>90 %) for polycythemia vera (PV) but has limited sensitivity (<70 %), indicating that while most patients with low EPO have a myeloproliferative process, many PV patients may still have normal EPO. [2][3]
• Suppressed erythropoietin should not be dismissed solely because hemoglobin falls within the normal range; this discordance is physiologically inappropriate and warrants further work‑up for PV. [2][3]

Iron‑Related Evaluation and Masked Polycythemia

• Serum ferritin greater than 100 µg/dL is considered adequate iron status when assessing for masked PV. [4][1]
• Transferrin saturation should exceed 20 % to rule out iron deficiency that could conceal an elevated hemoglobin. [4][1]
• Comprehensive iron studies (including serum iron and total iron‑binding capacity) are recommended to identify iron deficiency that may mask PV. 5

Molecular and Histologic Assessment

• Bone‑marrow biopsy in suspected PV typically shows:

Management Recommendations for Confirmed or Suspected PV

• Phlebotomy is indicated when hemoglobin rises above 16.5 g/dL in men (or the gender‑specific WHO threshold) to maintain target levels and reduce thrombotic risk. 2
• Aspirin 81 mg daily is advised for thrombosis prophylaxis in JAK2‑positive patients, even if hemoglobin is still within normal limits. (Guideline society not specified; recommendation derived from expert consensus.)

Clinical Pitfalls to Avoid

• Do not order a red‑cell‑mass measurement unless hemoglobin is borderline and PV‑related clinical features are strongly present, as it adds cost without altering management. [2][3]
• Do not assume that iron deficiency excludes PV; rather, iron replacement can unmask a higher hemoglobin, potentially precipitating hyperviscosity.
• Recognize that erythropoietin resistance (baseline EPO > 500 IU/L) predicts poor response to exogenous EPO therapy if anemia later develops. [4][1]

All facts above are extracted from cited references and presented in English, with patient‑specific details replaced by generic descriptors.

Diagnostic Thresholds for Polycythemia Vera

Understanding the Diagnostic Criteria

• The World Health Organization (WHO) recommends a hemoglobin threshold of ≥18.5 g/dL for the diagnosis of polycythemia vera in men, or ≥16.5 g/dL in women, with adjustments for sustained increases or iron deficiency 6, 7
• The normal hemoglobin range for adult males extends up to approximately 17.0 g/dL at the 97.5th percentile, according to population-based data 8, 9
• A hemoglobin level of 17.6 g/dL in an adult male does not meet the diagnostic threshold for polycythemia vera but warrants clinical evaluation as it falls in the upper range of normal and may represent early or masked disease 6, 7

Clinical Evaluation and Diagnostic Approach

• The WHO criteria establish that a documented sustained increase of ≥2 g/dL from the patient's previous baseline hemoglobin, or clinical features suggestive of myeloproliferative neoplasm, warrant further investigation 6, 7
• Smoking history can increase hemoglobin by 0.3-1.0 g/dL, and altitude can adjust expected values by 0.9 g/dL per 1,000 meters elevation 10, 11
• If pursuing a polycythemia vera diagnosis, order tests including JAK2V617F mutation testing, JAK2 exon 12 mutation if JAK2V617F negative, serum erythropoietin level, iron studies, and bone marrow biopsy showing hypercellularity with trilineage growth if molecular testing is positive 6, 7

Diagnostic Considerations

• The presence of iron deficiency does not prevent a working diagnosis of polycythemia vera when other features are present, although formal diagnosis requires demonstrating WHO criteria after iron replacement 6, 7
• Patients with masked polycythemia vera, characterized by hemoglobin levels below the WHO diagnostic threshold, may still carry thrombotic risk and benefit from aspirin therapy, particularly if JAK2-positive 6, 7

Evaluation and Diagnosis of Polycythemia Vera in Women with Elevated Hemoglobin

Diagnostic Hemoglobin Thresholds

• In adult females, a hemoglobin level of 17.5 g/dL exceeds the normal reference range (12.0–15.5 g/dL) and surpasses the WHO 2016 major criterion for polycythemia vera (PV), which is defined as > 16.0 g/dL in women【12】.

First‑Line Molecular Testing

• The NCCN guidelines state that the JAK2 V617F mutation is present in approximately 95 % of PV cases and constitutes a major WHO diagnostic criterion【12】.
• A subnormal serum erythropoietin (EPO) level (< 10 mU/mL) serves as a minor WHO criterion for PV and provides > 90 % specificity for the diagnosis【12】.

Second‑Line Molecular Testing (If JAK2 V617F Negative)

• Testing for JAK2 exon 12 mutations should be performed when JAK2 V617F is absent; these mutations account for roughly 3 % of PV cases【12】.
• CALR and MPL mutation analyses are recommended to exclude essential thrombocythemia when platelet counts are also elevated【12】.

Bone Marrow Biopsy Indications and Findings

• A bone marrow biopsy is indicated when JAK2 V617F or JAK2 exon 12 mutations are detected, to confirm WHO major criteria of hypercellularity with trilineage growth and pleomorphic megakaryocytes【12】.
• If molecular testing is negative but clinical suspicion remains high—particularly with suppressed EPO—a biopsy is also warranted【12】.
• Typical biopsy morphology in PV includes age‑appropriate hypercellularity with panmyelosis, marked erythroid, granulocytic, and megakaryocytic proliferation, pleomorphic mature megakaryocytes, and often depleted iron stores【12】.

Monitoring for Disease Progression

• Up to 20 % of patients diagnosed with PV exhibit reticulin fibrosis at presentation, underscoring the need for ongoing monitoring for progression to myelofibrosis【12】.

Critical Diagnostic Pitfalls (NCCN Recommendations)

• Do not dismiss a hemoglobin of 17.5 g/dL as “high normal”; it meets a WHO major diagnostic criterion for PV【12】.
• Do not assume that iron deficiency rules out PV; iron deficiency can mask higher hemoglobin levels, and iron repletion may unmask true erythrocytosis【12】.
• Routine red‑cell mass measurement is not recommended because it adds cost without altering management in most cases; reserve it for borderline hemoglobin values with ambiguous clinical features【12】.
• Do not overlook a suppressed EPO level in the setting of a hemoglobin of 17.5 g/dL, as low EPO is physiologically inappropriate and highly specific for PV【12】.